1. Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
- Author
-
Mariano Provencio, Pilar Sabín, Jose Gomez-Codina, Maria Torrente, Virginia Calvo, Marta Llanos, Josep Gumá, Cristina Quero, Ana Blasco, Miguel Angel Cruz, David Aguiar, Francisco García-Arroyo, Javier Lavernia, Natividad Martinez, Manuel Morales, Alvaro Saez-Cusi, Delvys Rodriguez, Luis de la Cruz, Jose Javier Sanchez, Antonio Rueda, GOTEL (Spanish Lymphoma Oncology Group), and UAM. Departamento de Medicina
- Subjects
Oncology ,Male ,Spanish People ,Survival ,Follicular lymphoma ,Cancer Treatment ,lcsh:Medicine ,Kaplan-Meier Estimate ,Hematologic Cancers and Related Disorders ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Medicine and Health Sciences ,Medicine ,Ethnicities ,Anthracyclines ,Prospective Studies ,Registries ,Young adult ,Prospective cohort study ,lcsh:Science ,Lymphoma, Follicular ,education.field_of_study ,Multidisciplinary ,Hispanic or Latino ,Hematology ,Middle Aged ,Prognosis ,Europe ,B symptoms ,030220 oncology & carcinogenesis ,Rituximab ,Lymphomas ,Female ,medicine.symptom ,Hispanic Americans ,medicine.drug ,Research Article ,Clinical Oncology ,Adult ,medicine.medical_specialty ,Medicina ,Population ,Radiation Therapy ,Disease-Free Survival ,03 medical and health sciences ,Young Adult ,Age Distribution ,Diagnostic Medicine ,Internal medicine ,Cancer Detection and Diagnosis ,Humans ,education ,Aged ,Proportional Hazards Models ,Performance status ,business.industry ,lcsh:R ,Cancers and Neoplasms ,medicine.disease ,Lymphoma ,Treatment ,People and Places ,lcsh:Q ,Population Groupings ,Clinical Medicine ,business ,030215 immunology - Abstract
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma. Patients and methods A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013. Results Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage < II (p < 0.03), age < 60 years (p < 0.0001), low FLIPI (p < 0.002), normal 2 microglobulin (p < 0.005), no B symptoms upon diagnosis (p < 0.02), Performance Status 0-1 (p < 0.03) and treatment with anthracyclines and rituximab (p < 0.001), or rituximab (p < 0.0001). Conclusions A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years.
- Published
- 2017